HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate Secures Rx-To-OTC Switch Of Duraphat In Norway

Executive Summary

Colgate's high-fluoride toothpaste Duraphat will soon be available OTC in Norway after the country switched the product into its new "non-prescription medicines with guidance" category.

You may also be interested in...



Pfizer Building Viagra As Pan-European Consumer Health Brand With Rx-To-OTC Switch In Norway

Pfizer has taken the first steps towards turning its Viagra erectile dysfunction treatment into a pan-European OTC brand by taking advantage of Norway's new "non-prescription medicines with guidance" category to secure the Rx-to-OTC switch of the product. Norway will be the second European market where Viagra is available OTC after the UK switched the drug in 2017.

People On The Move: Appointments At CRN UK, EMA, Boots

A round-up of the latest European executive appointments: CRN UK hires scientific advisor; EMA management board names vice chair; Boots UK appoints chief digital officer.

France's Havea Set For New Private-Equity Owners

French natural consumer health specialist Havea looks set to be snapped up by private-equity firm BC Partners, which has set out a plan to step up the company's M&A and digitization activities. 

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS150649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel